中重度活动性溃疡性结肠炎一线与二线药物治疗:更新的网络Meta分析
该网络Meta分析比较了中重度活动性溃疡性结肠炎一线(生物制剂初治)与二线(既往TNF拮抗剂暴露)药物的疗效与安全性。结果显示,生物制剂初治患者中英夫利西单抗诱导缓解和內镜改善排名最高;既往TNF拮抗剂暴露患者中乌司奴单抗和托法替尼排名最高,且优于维得利珠单抗和阿达木单抗。维持治疗中维得利珠单抗感染风险最低。
要点
- 生物制剂初治患者中英夫利西单抗诱导临床缓解和内镜改善排名最高。
- 既往TNF拮抗剂暴露患者中乌司奴单抗和托法替尼诱导缓解排名最高。
- 维持治疗中维得利珠单抗感染风险最低,乌司奴单抗次之。
核心结论
- 生物制剂初治患者中英夫利西单抗在诱导缓解和内镜改善方面排名最高。
- 既往TNF拮抗剂暴露患者中乌司奴单抗和托法替尼在诱导缓解方面排名最高。
- 维持治疗中维得利珠单抗感染风险最低,乌司奴单抗次之。
研究设计与样本
- 系统检索截至2019年9月30日的随机对照试验,纳入中重度活动性溃疡性结肠炎成人患者。
- 比较TNF拮抗剂、维得利珠单抗、托法替尼或乌司奴单抗作为一线或二线药物与安慰剂或其他活性药物的疗效。
- 采用频率学派固定效应网络Meta分析,计算比值比(OR)和95%CI,并使用SUCRA概率排序和GRADE评级。
主要发现
- 生物制剂初治患者中,英夫利西单抗诱导临床缓解的OR vs 安慰剂为4.07(95%CI 2.67-6.21),SUCRA为0.95。
- 既往TNF拮抗剂暴露患者中,乌司奴单抗诱导临床缓解SUCRA为0.87,托法替尼SUCRA为0.87。
- 乌司奴单抗 vs 维得利珠单抗诱导缓解OR为5.99(95%CI 1.13-31.76),托法替尼 vs 维得利珠单抗OR为6.18(95%CI 1.003-8.00)。
- 乌司奴单抗 vs 阿达木单抗诱导缓解OR为10.71(95%CI 2.01-57.20),托法替尼 vs 阿达木单抗OR为11.05(95%CI 1.79-68.41)。
- 维持治疗中维得利珠单抗感染风险最低(SUCRA 0.81),乌司奴单抗次之(SUCRA 0.63)。
临床怎么用
- 生物制剂初治的中重度活动性溃疡性结肠炎患者可优先考虑英夫利西单抗诱导治疗。
- 既往TNF拮抗剂暴露的患者可优先考虑乌司奴单抗或托法替尼诱导治疗。
- 维持治疗需权衡感染风险时,可优先考虑维得利珠单抗或乌司奴单抗。
局限性
- 需要更多直接比较试验以提供更高置信度的临床决策依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naïve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moderate to severely active ulcerative colitis in a systematic review and network meta-analysis. METHODS: We searched publication databases through September 30, 2019, for randomized trials of adults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab, tofacitinib, or ustekinumab, as first-line or second-line agents, compared with placebo or another active agent. Efficacy outcomes were induction and maintenance of remission and endoscopic improvement; safety outcomes were serious adverse events and infections. We performed a fixed-effects network meta-analysis using the frequentist approach, and calculated odds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative ranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of Recommendations, Assessment, Development and Evaluation). RESULTS: In biologic-naïve patients, infliximab was ranked highest for induction of clinical remission (OR vs placebo, 4.07; 95% CI, 2.67-6.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95) (moderate confidence in estimates [CE]). In patients with prior exposure to TNF antagonists, ustekinumab (SUCRA, 0.87) and tofacitinib (SUCRA, 0.87) were ranked highest for induction of clinical remission and were superior to vedolizumab (ustekinumab vs vedolizumab: OR, 5.99; 95% CI, 1.13-31.76 and tofacitinib vs vedolizumab: OR, 6.18; 95% CI, 1.003-8.00; moderate CE) and adalimumab (ustekinumab vs adalimumab: OR, 10.71; 95% CI, 2.01-57.20 and tofacitinib vs adalimumab: OR, 11.05; 95% CI, 1.79-68.41; moderate CE). Vedolizumab had the lowest risk of infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials. CONCLUSIONS: In a systematic review and network meta-analysis, we found infliximab to be ranked highest in biologic-naïve patients, and ustekinumab and tofacitinib were ranked highest in patients with prior exposure to TNF antagonists, for induction of remission and endoscopic improvement in patients with moderate to severe ulcerative colitis. More trials of direct comparisons are needed to inform clinical decision making with greater confidence.
引用
- Singh S, Murad MH, Fumery M, et al. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020. PMID: 31945470. doi:10.1016/j.cgh.2020.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。